Pfizer's (PFE) venture arm has placed its latest targeted therapeutics bet yet by leading a $15.5 million round for the development stage cancer and autoimmune diagnostics company Nodality. The money will support Nodality’s launch of its first test for acute myelogenous leukemia, one of the most common types of the bone marrow cancer in adults. It will also help advance Nodality's other R&D programs in other hematologic malignancies, autoimmune diseases, and solid tumors, the South San Francisco, California-based company says.
LabCorp, Kleiner Perkins, TPG Biotechnology and Maverick Capital also participated in the round.
No comments:
Post a Comment